Nivolumab Retreatment After Immune-Related Colitis and Hepatitis Following Combination Ipilimumab-Nivolumab in Melanoma: Safety, Recurrence Risk and Early Efficacy (ESMO Asia 2026) - Oct 1, 2026 - Abstract #851P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Melanoma • Oncology • Solid Tumor
|
|
Anjali Kashyap; Samantha Hopkins; Felicity Martin; Jason Qin; Annie N. Wong; Andrew Trinh; Jonathan Segal; Shahneen K. Sandhu; Lavinia Spain
|